Generex AE37 Prostate Cancer Vaccine Part of Recent Study

Generex AE37 Prostate Cancer Vaccine Part of Recent Study
immunologyGenerex Biotechnology Corporation, a company focused on the research and development of drug delivery systems and technologies, has announced a follow-up study from its Phase I clinical trial of the immunotherapeutic agent AE37 in patients with prostate cancer. Prostate cancer is the second most common cancer in men worldwide, and the 6th leading caus
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *